Close Menu

Biocartis

An expansion of its oncology test menu helped drive installations of its Idylla molecular diagnostics system and cartridge sales in the first half of 2016.

Assessments of the firm's rapid molecular BRAF and EGFR tests by researchers in Italy and South Korea showed high sensitivity and a fast turnaround time.

The Belgian molecular diagnostics company said it will focus on expanding its capability to manufacture its Idylla diagnostics.

Researchers also found that higher frequencies of BRAF V600E mutations in the blood were associated with poorer outcomes and less responsiveness to BRAF inhibitors.

The spike in collaboration revenue offset a drop in product revenue while the firm anticipates several key regulatory approvals in the coming year.

The tests analyze tumor samples for mutations oncogenes including KRAS and NRAS in order to help guide treatment decisions for patients with metastatic colorectal cancer.

The new test will be based on Biocartis' Idylla PCR-based diagnostics platform and will detect an extended panel of RAS mutations, plus BRAF V600 mutations.

The assay runs on the company's fully automated PCR-based Idylla platform and detects various strains of the flu virus and respiratory syncytial virus.

The company will use the money to develop liquid biopsy versions of its solid tumor BRAF and KRAS diagnostics as part of a larger research collaboration.

The company's revenues rose nearly 500 percent year over year, driven by collaboration revenues received from Janssen Pharmaceutica.

Pages

Retraction Watch reports that a paper was pulled because it refers to a gene that doesn't exist in mice.

Researchers were able to generate fertilized northern white rhinoceros eggs, according to Mashable.

Former Orig3n employees raise concerns about its testing at Bloomberg Businessweek.

In PLOS this week: microRNA expression changes in hepatocellular carcinoma, real-time PCR-based approach for diagnosing schistosomiasis, and more.